Literature DB >> 33427510

Novel approaches to fertility restoration in women with premature ovarian insufficiency.

R Rosario1, R A Anderson1.   

Abstract

The diagnosis of premature ovarian insufficiency (POI) brings with it the loss of fertility, an immediate concern for many affected women, and a future one for many others. While there is a low natural conception rate, for most the choice is between oocyte donation and alternative methods of family building such as adoption. There is, however, a lot of research into novel methods for increasing or restoring the fertility of women with POI, which are discussed in this review. Many approaches involve the use of mesenchymal stem cells, from a variety of sources including bone marrow, placenta and umbilical cord, and menstrual blood. These seem to have efficacy in animal models of POI, although through unclear mechanisms. Activation of remaining primordial follicles is also being explored, through physical or chemical manipulation of key regulatory pathways, notably the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) and Hippo pathways. Much of the clinical data are uncontrolled, and mostly in women with a reduced ovarian reserve rather than POI, as are the results thus far for administration of platelet-rich plasma. Clinical studies with appropriate controls are needed to substantiate the preliminary claims of effectiveness of these approaches.

Entities:  

Keywords:  Premature ovarian insufficiency; mesenchymal stem cell; platelet-rich plasma; primordial follicle activation; treatment

Mesh:

Year:  2021        PMID: 33427510     DOI: 10.1080/13697137.2020.1856806

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  1 in total

Review 1.  The Trends and Hotspots in Premature Ovarian Insufficiency Therapy from 2000 to 2022.

Authors:  Yan Tong; Nan Cheng; Xinran Jiang; Kai Wang; Fei Wang; Xinxin Lin; Fang Wang
Journal:  Int J Environ Res Public Health       Date:  2022-09-17       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.